SG10201601846VA - Rnai inhibition of alpha-enac expression - Google Patents
Rnai inhibition of alpha-enac expressionInfo
- Publication number
- SG10201601846VA SG10201601846VA SG10201601846VA SG10201601846VA SG10201601846VA SG 10201601846V A SG10201601846V A SG 10201601846VA SG 10201601846V A SG10201601846V A SG 10201601846VA SG 10201601846V A SG10201601846V A SG 10201601846VA SG 10201601846V A SG10201601846V A SG 10201601846VA
- Authority
- SG
- Singapore
- Prior art keywords
- alpha
- enac expression
- rnai inhibition
- rnai
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07110376 | 2007-06-15 | ||
EP07114265 | 2007-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201601846VA true SG10201601846VA (en) | 2016-04-28 |
Family
ID=40130244
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201404955RA SG10201404955RA (en) | 2007-06-15 | 2008-06-13 | Rnai inhibition of alpha-enac expression |
SG201101084-0A SG169988A1 (en) | 2007-06-15 | 2008-06-13 | Rnai inhibition of alpha-enac expression |
SG10201601846VA SG10201601846VA (en) | 2007-06-15 | 2008-06-13 | Rnai inhibition of alpha-enac expression |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201404955RA SG10201404955RA (en) | 2007-06-15 | 2008-06-13 | Rnai inhibition of alpha-enac expression |
SG201101084-0A SG169988A1 (en) | 2007-06-15 | 2008-06-13 | Rnai inhibition of alpha-enac expression |
Country Status (26)
Country | Link |
---|---|
US (12) | US7718632B2 (es) |
EP (7) | EP2223694B1 (es) |
JP (6) | JP5485146B2 (es) |
KR (2) | KR101821081B1 (es) |
CN (1) | CN101778941B (es) |
AR (1) | AR066984A1 (es) |
AU (1) | AU2008263876B2 (es) |
BR (1) | BRPI0813680A8 (es) |
CA (1) | CA2690674C (es) |
CL (1) | CL2008001756A1 (es) |
CO (1) | CO6251331A2 (es) |
CR (1) | CR11136A (es) |
CU (1) | CU23774A3 (es) |
EA (1) | EA200901653A1 (es) |
EC (1) | ECSP099794A (es) |
ES (6) | ES2432157T3 (es) |
GT (1) | GT200900315A (es) |
IL (1) | IL202366A0 (es) |
MA (1) | MA31564B1 (es) |
MX (1) | MX2009013609A (es) |
PE (1) | PE20090942A1 (es) |
SG (3) | SG10201404955RA (es) |
SV (1) | SV2009003434A (es) |
TN (1) | TN2009000521A1 (es) |
TW (3) | TWI629063B (es) |
WO (1) | WO2008152131A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4709545B2 (ja) * | 2002-07-26 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 修飾された低分子干渉rna分子および使用方法 |
KR100473148B1 (ko) * | 2002-11-27 | 2005-03-10 | (주)텔리언 | 버스트모드 패킷 전달을 위한 정합장치 및 방법 |
WO2006039656A2 (en) * | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Inc. | Modified small interfering rna molecules and methods of use |
US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
US20110288154A1 (en) * | 2008-11-26 | 2011-11-24 | Merck & Co., Inc. | RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
CN103275978B (zh) * | 2009-04-03 | 2014-10-29 | 百奥迈科生物技术有限公司 | 修饰的小干扰核酸及其制备方法 |
WO2010111891A1 (zh) * | 2009-04-03 | 2010-10-07 | 北京大学 | 修饰的寡聚核酸分子及其制备方法和应用 |
EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
US20120207818A1 (en) * | 2009-07-14 | 2012-08-16 | Shinohara Fumikazu | Composition for suppressing expression of target gene |
WO2011046983A2 (en) * | 2009-10-12 | 2011-04-21 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2011073326A2 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
WO2011131707A1 (en) | 2010-04-23 | 2011-10-27 | Novartis Ag | ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES |
EP2694670B1 (en) | 2011-04-08 | 2017-07-19 | Bio-Rad Laboratories, Inc. | Pcr reaction mixtures with decreased non-specific activity |
JP2014519806A (ja) | 2011-04-20 | 2014-08-21 | スミス ホールディングス,エルエルシー | 細胞内で自己会合し、RNAi活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分 |
CA3185394A1 (en) | 2011-09-02 | 2013-03-07 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
KR102634762B1 (ko) | 2016-11-01 | 2024-02-06 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-v 베타-6 인테그린 리간드 및 그의 용도 |
CA3061752A1 (en) * | 2017-07-06 | 2019-01-10 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of alpha-enac and methods of use |
PE20200749A1 (es) * | 2017-10-31 | 2020-07-24 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de enac |
TN2020000059A1 (en) | 2017-11-01 | 2022-01-06 | Arrowhead Pharmaceuticals Inc | Integrin ligands and uses thereof |
CN109364248B (zh) * | 2018-10-16 | 2021-05-18 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
US20220339136A1 (en) * | 2019-08-30 | 2022-10-27 | United States Government As Represented By The Department Of Veterans Affairs | Liposomal troponoid compound formulations |
US11957178B2 (en) | 2021-11-15 | 2024-04-16 | Apackaging Group Llc | Aerosol actuator |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4837026A (en) * | 1985-10-03 | 1989-06-06 | Rajakhyaksha Vithal J | Transdermal and systemic preparation and method |
DE3604625C2 (de) * | 1986-02-14 | 1994-01-20 | Bmw Rolls Royce Gmbh | Gasturbine |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US5451670A (en) * | 1987-12-09 | 1995-09-19 | City Of Hope | Restriction fragment length polymorphism test for haplotyping domesticated fowl |
GB8824593D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5013566A (en) * | 1988-12-19 | 1991-05-07 | Sampson Michael James | Process for obtaining improved yields from plants used for hay making by using a coating agent |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5665710A (en) | 1990-04-30 | 1997-09-09 | Georgetown University | Method of making liposomal oligodeoxynucleotide compositions |
JP3220180B2 (ja) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
JP3351476B2 (ja) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | リン脂質誘導体及びそれを含有するリポソーム |
WO1994018987A1 (en) | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Drug composition containing nucleic acid copolymer |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US5540935A (en) | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
JP3543347B2 (ja) * | 1994-01-24 | 2004-07-14 | 日本油脂株式会社 | 点火薬造粒物の製造方法 |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
DE69629702T2 (de) | 1995-08-01 | 2004-06-17 | Isis Pharmaceuticals, Inc., Carlsbad | Liposomale oligonukleotidzusammensetzungen |
US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US6218108B1 (en) | 1997-05-16 | 2001-04-17 | Research Corporation Technologies, Inc. | Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor |
US5865710A (en) * | 1996-08-01 | 1999-02-02 | Wilson-Hyde; Cynthia | Step aerobic platform |
EP0975798A1 (en) * | 1997-03-11 | 2000-02-02 | Yale University | Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1 |
US6887906B1 (en) | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
US5976849A (en) | 1998-02-05 | 1999-11-02 | Zeneca Limited | Human E3 ubiquitin protein ligase |
WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
JP4095895B2 (ja) * | 2000-12-01 | 2008-06-04 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Rna干渉を媒介する短鎖rna分子 |
CN1526025A (zh) | 2001-05-16 | 2004-09-01 | ��˹��ŵ�� | 作为预后和治疗靶标的乳腺癌中表达的基因 |
WO2003057847A2 (en) | 2001-12-31 | 2003-07-17 | Algos Therapeutics , Inc. | METHODS AND MATERIALS FOR MODULATING ENaC-BETA |
JP4709545B2 (ja) | 2002-07-26 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 修飾された低分子干渉rna分子および使用方法 |
JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
GB0218970D0 (en) | 2002-08-14 | 2002-09-25 | Creative Peptides Sweden Ab | Fragments of Insulin c-peptide |
EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
EP1573045A4 (en) | 2002-11-27 | 2007-02-21 | Artesian Therapeutics Inc | DETECTION OF GENES RELATED TO HEART FAILURE AND THERAPEUTIC ASSAY |
BRPI0215958B1 (pt) | 2002-11-29 | 2016-11-08 | Basf Ag | métodos para produção de metionina |
DE10305213A1 (de) | 2003-02-07 | 2004-08-26 | Florian Prof. Dr.med. Lang | Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms |
AU2004227915A1 (en) * | 2003-03-31 | 2004-10-21 | John F. Engelhardt | Pharmico-gene theraphy of epithelial sodium channel associated disoders |
US7723509B2 (en) * | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
US20050256071A1 (en) * | 2003-07-15 | 2005-11-17 | California Institute Of Technology | Inhibitor nucleic acids |
JP4530335B2 (ja) * | 2004-02-03 | 2010-08-25 | 独立行政法人科学技術振興機構 | 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬 |
EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
SE0402832D0 (sv) * | 2004-11-18 | 2004-11-18 | Astrazeneca Ab | Methods |
US7923206B2 (en) * | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
AU2005316384B2 (en) * | 2004-12-14 | 2012-02-09 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
WO2007070509A2 (en) * | 2005-12-13 | 2007-06-21 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Epithelial sodium channel inhibiting agents and uses therefor |
SG166778A1 (en) | 2006-10-11 | 2010-12-29 | Max Planck Gesellschaft | Influenza targets |
AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
-
2008
- 2008-06-12 AR ARP080102518A patent/AR066984A1/es not_active Application Discontinuation
- 2008-06-13 ES ES10163499T patent/ES2432157T3/es active Active
- 2008-06-13 PE PE2008001013A patent/PE20090942A1/es not_active Application Discontinuation
- 2008-06-13 EP EP10163501.9A patent/EP2223694B1/en active Active
- 2008-06-13 TW TW105120348A patent/TWI629063B/zh active
- 2008-06-13 CN CN2008801032623A patent/CN101778941B/zh active Active
- 2008-06-13 TW TW103118914A patent/TWI552753B/zh active
- 2008-06-13 BR BRPI0813680A patent/BRPI0813680A8/pt active IP Right Grant
- 2008-06-13 KR KR1020167023121A patent/KR101821081B1/ko active IP Right Grant
- 2008-06-13 JP JP2010511658A patent/JP5485146B2/ja active Active
- 2008-06-13 EP EP10163500.1A patent/EP2223693B1/en active Active
- 2008-06-13 CA CA2690674A patent/CA2690674C/en active Active
- 2008-06-13 ES ES10163501T patent/ES2432158T3/es active Active
- 2008-06-13 EA EA200901653A patent/EA200901653A1/ru unknown
- 2008-06-13 SG SG10201404955RA patent/SG10201404955RA/en unknown
- 2008-06-13 ES ES10163496T patent/ES2432643T3/es active Active
- 2008-06-13 ES ES10163502T patent/ES2432532T3/es active Active
- 2008-06-13 EP EP10163499.6A patent/EP2223692B1/en active Active
- 2008-06-13 CL CL2008001756A patent/CL2008001756A1/es unknown
- 2008-06-13 EP EP10163498.8A patent/EP2224005B1/en active Active
- 2008-06-13 ES ES10163498.8T patent/ES2439277T3/es active Active
- 2008-06-13 SG SG201101084-0A patent/SG169988A1/en unknown
- 2008-06-13 EP EP10163502.7A patent/EP2223695B1/en active Active
- 2008-06-13 TW TW097122240A patent/TWI444474B/zh active
- 2008-06-13 SG SG10201601846VA patent/SG10201601846VA/en unknown
- 2008-06-13 EP EP10163496.2A patent/EP2224004B1/en active Active
- 2008-06-13 EP EP08761002A patent/EP2171059A2/en not_active Withdrawn
- 2008-06-13 MX MX2009013609A patent/MX2009013609A/es active IP Right Grant
- 2008-06-13 ES ES10163500T patent/ES2432644T3/es active Active
- 2008-06-13 AU AU2008263876A patent/AU2008263876B2/en not_active Ceased
- 2008-06-13 WO PCT/EP2008/057476 patent/WO2008152131A2/en active Application Filing
- 2008-06-13 KR KR1020107000840A patent/KR101653008B1/ko active IP Right Grant
- 2008-06-16 US US12/140,112 patent/US7718632B2/en active Active
-
2009
- 2009-11-26 IL IL202366A patent/IL202366A0/en unknown
- 2009-12-02 CR CR11136A patent/CR11136A/es not_active Application Discontinuation
- 2009-12-11 CO CO09142201A patent/CO6251331A2/es not_active Application Discontinuation
- 2009-12-11 EC EC2009009794A patent/ECSP099794A/es unknown
- 2009-12-11 GT GT200900315A patent/GT200900315A/es unknown
- 2009-12-11 TN TNP2009000521A patent/TN2009000521A1/fr unknown
- 2009-12-14 SV SV2009003434A patent/SV2009003434A/es unknown
- 2009-12-15 CU CU20090215A patent/CU23774A3/es not_active IP Right Cessation
-
2010
- 2010-01-06 US US12/683,146 patent/US9074212B2/en active Active
- 2010-01-07 MA MA32484A patent/MA31564B1/fr unknown
- 2010-04-30 US US12/771,614 patent/US8168606B2/en active Active
- 2010-04-30 US US12/771,518 patent/US7939508B2/en active Active
- 2010-04-30 US US12/771,470 patent/US7943592B2/en active Active
- 2010-04-30 US US12/771,566 patent/US8119612B2/en active Active
-
2014
- 2014-02-19 JP JP2014029519A patent/JP5719047B2/ja active Active
-
2015
- 2015-03-19 JP JP2015055783A patent/JP6193906B2/ja active Active
- 2015-06-03 US US14/729,104 patent/US9476052B2/en active Active
-
2016
- 2016-09-09 US US15/260,824 patent/US9914927B2/en active Active
-
2017
- 2017-08-01 JP JP2017149211A patent/JP6680728B2/ja active Active
-
2018
- 2018-01-18 US US15/874,396 patent/US10544418B2/en active Active
-
2020
- 2020-01-24 US US16/752,325 patent/US11208662B2/en active Active
- 2020-03-17 JP JP2020046007A patent/JP7157775B2/ja active Active
-
2021
- 2021-12-23 US US17/560,475 patent/US20220112505A1/en not_active Abandoned
-
2022
- 2022-04-05 US US17/713,763 patent/US20220235361A1/en not_active Abandoned
- 2022-10-07 JP JP2022162309A patent/JP2022188234A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL202366A0 (en) | RNAi INHIBITION OF ALPHA-ENAC EXPRESSION | |
GB0818498D0 (en) | Provision of inserts | |
ZA200906946B (en) | Inhibitors of iap | |
EP2341943A4 (en) | COMPOSITIONS AND METHODS FOR SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA OWING MODIFICATIONS | |
ZA201000318B (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
EP2317847A4 (en) | SELECTIVE INHIBITION OF POLYGLUTAMINE PROTEIN EXPRESSION | |
EP2192838A4 (en) | HETEROCYCLIC NEKROPTOSIS HEMMER | |
EP2318395A4 (en) | IPA INHIBITORS | |
EP2282755A4 (en) | INHIBITION OF ANGIOGENESIS | |
ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
HK1142128A1 (en) | Methods of prognosis | |
EP2212430A4 (en) | REDUCED PCR INHIBITION OF RT IN ONE STEP | |
GB0719997D0 (en) | Portease Inhibition | |
PL2133419T3 (pl) | Zastosowania beta-dipeptydów cyjanoficyny | |
ZA201004765B (en) | Inhibitors of iap | |
HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
GB0817926D0 (en) | Articles of clothiing | |
GB0916334D0 (en) | Inhibition of tendon adhesions | |
EP2142188A4 (en) | PROCESS FOR SUPPRESSING LTP INHIBITION | |
GB0701722D0 (en) | Inhibition of gene expression | |
GB0724962D0 (en) | Scale inhibition | |
GB0802009D0 (en) | Biomarkers of aminopeptidase inhibition | |
PL2411376T3 (pl) | Inhibitory nf-kb | |
ZA200908301B (en) | Rnai inhibition of alpha-enac expression | |
GB201114396D0 (en) | Location of basesation |